Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Vascular Health and Risk Management Volume 2, 2006 - Issue 2

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Editorial Foreword

Risk of Cardiovascular Events and Cyclooxygenase-2 Inhibitors

Reza TabrizchiDivision of Basic Medical Sciences, Faculty of Medicine, Memorial University of NewfoundlandSt John's, NL, Canada

Pages 95-96 | Published online: 24 Dec 2022

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

BrockTGMcNishRWPeters-GoldenMArachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2J Biol Chem199927411660610206978
PubMed Web of Science ®Google Scholar
CaldwellBAldingtonSWeatherallMRisk of cardiovascular events and celecoxib: a systematic review and meta-analysisJ R Soc Med2006991324016508052
PubMed Web of Science ®Google Scholar
Catella-LawsonFMcAdamBMorrisonBWEffects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoidsJ Pharmacol Exp Ther19992897354110215647
PubMed Web of Science ®Google Scholar
Catella-LawsonFVascular biology of thrombosisNeurology200157Suppl 2S5S711552047
PubMedGoogle Scholar
JüniPNarteyLReichenbachSRisk of cardiovascular events and rofecoxib: cumulative meta-analysisLancet20043642021915582059
PubMed Web of Science ®Google Scholar
McAdamBFCatella-LawsonFMardiniIASystemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2Proc Natl Acad Sci U S A19999627279874808
PubMed Web of Science ®Google Scholar
TabrizchiRCoxibs: can this class of drugs survive?Vasc Health Risk Manag200515817319092
PubMedGoogle Scholar
VinalsMMartinez-GonzalezJBadimonJJHDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2)Arterioscler Thromb Vasc Biol199717348189437196
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references